Capricor Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
1
1
2
2
2
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative therapeutic approaches by leveraging its expertise in regenerative medicine, cellular therapies, and exosome technology to address significant unmet medical needs.Explore more
Capricor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Capricor Therapeutics is spiking on competitors!
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Product Launch: Get notified when Capricor Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$204.6M
201-500
Public
$466M
1990
Bryan RidgellSenior Vice President, Portfolio and Project Management, and Chief of Staff
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2024
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
See more technologies
Most Recent Scoops
Project
Capricor Therapeutics has administered approximately 1,300 intravenous infusions of Deramiocel to over 200 patients with Duchenne muscular dystrophy (DMD) across three clinical trials, with more than 80 patients enrolled in open-label extension studies, some receiving continuous infusions for more than five years, demonstrating a consistent and well-characterized long-term safety profile.
Clinical Operations
Project
Capricor Therapeutics has identified expansion of Deramiocel clinical trials to younger Duchenne muscular dystrophy (DMD) patients and patients with Becker muscular dystrophy as priorities, with the timing of those trial initiations contingent on the regulatory pathway for Deramiocel in the United States.
Medical Research, Clinical Operations
Project
reported that the HOPE-3 primary endpoint for Deramiocel was unaffected by the statistical model correction, with Deramiocel demonstrating a statistically significant slowing of upper limb disease progression as measured by PUL 2.0, showing a mean difference of 4.55% in favor of Deramiocel with a p-value of 0.029, corresponding to a 1.2-point absolute change in PUL 2.0.
Medical Research
Project
plans to submit an amendment to its BLA for Deramiocel that includes 24-month open-label extension data from the HOPE-3 study, along with additional analyses, to support a refined indication focused on an upper limb skeletal muscle indication; the FDA has indicated it is willing to review the amendment and will extend the PDUFA action date upon receipt.
Medical Research
Person-Based
Earnings, Financial Reporting, Finance
Capricor Therapeutics News & Media
NASDAQ: CAPR LAWSUIT ALERT: Investors who lost money with shares of Capricor Therapeutics, Inc.should contact the Shareholders Foundation
SAN DIEGO, Sept. 15, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR). NASDAQ: CAPR investors should contact the Shareholders Foundation at...CAPR Court Alert: Capricor Therapeutics Securities Fraud Class Action Deadline is Approaching on September 28 for Investors that Suffered Losses
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Leading securities law firm...CAPR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their OptionsDeadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
LOS ANGELES, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 inclusive (the “Class Period”).
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Capricor Therapeutics
Sign Up For FreeTo access detailed company insights
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative... Read More
